Bloc auriculo-venticulaire congenital complet et anticorps anti-Ro (SSA) et anti-La (SSB)

Translated title of the contribution: Anti-Ro (SSA) and anti-La (SSB) antibodies and complete congenital heart block

Yaron Finkelstein*, Yehuda Adler, Liora Harel, Moshe Nussinovitch, Pierre Youinou

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Complete congenital heart block (CCHB) is the most severe manifestation of neonatal lupus syndrome, associated with a mortality rate of up to 31%. It is caused by irreversible damage to the cardiac conduction system due to the transplacental passage of maternal antibodies to the fetus. Anti-Ro (SSA) and anti-La (SSB) antibodies are usually detected in sera of mothers of children with prenatally diagnosed CCHB and in cardiac tissues of affected newborns. Their pathogeneic role in the development of CCHB has been established in several studies. When CCHB is detected during pregnancy, careful monotiring and delivery are needed before heart failure is developed. Treatment strategies are debatable and may include prophylactic therapy for high-risk pregnant women and a combination of intrauterine plasmapheresis with plasma exchange or with corticosteroids. Pacemaker insertion is required in most infants during the first three months of life. Assays for anti-Ro (SSA) and anti-La (SSB) antibodies should be performed on sera of pregnant women with SLE and newborns with CCHB.

Translated title of the contributionAnti-Ro (SSA) and anti-La (SSB) antibodies and complete congenital heart block
Original languageFrench
Pages (from-to)205-208
Number of pages4
JournalAnnales de Medecine Interne
Issue number3
StatePublished - 1997


  • Anti-La (SSB)
  • Anti-Ro (SSA)
  • Congenital heart block


Dive into the research topics of 'Anti-Ro (SSA) and anti-La (SSB) antibodies and complete congenital heart block'. Together they form a unique fingerprint.

Cite this